Introduction
Osteoarthritis (OA) is a prevalent joint disease characterized by articular cartilage degeneration, leading to pain and functional limitations. With an aging global population, OA's incidence and economic burden are projected to increase. Traditional pharmacological treatments, including paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs), have raised safety concerns, prompting the exploration of alternative therapies such as collagen derivatives. This review aims to summarize and disseminate the findings of a comprehensive scoping
study (PMC7695755) on the effects of collagen derivatives in OA and cartilage repair.
Background on Osteoarthritis
Osteoarthritis is the most common joint disease, significantly impairing the quality of life of millions due to chronic pain and reduced physical function. Weight-bearing joints, such as the knees and hips, are particularly affected. Despite the widespread use of symptomatic treatments, there are currently no disease-modifying drugs available for OA. This has led researchers to explore alternative therapies to alleviate symptoms and potentially repair or slow cartilage degradation.
Traditional Treatments and Their Limitations
Paracetamol and NSAIDs have been the mainstay treatments for OA, aimed at reducing pain and improving physical function. However, recent studies have questioned their safety and efficacy. Paracetamol, once recommended as the first-line therapy, has been downgraded in recent guidelines due to concerns about its effectiveness and safety profile. Similarly, NSAIDs are associated with adverse effects, particularly in patients with comorbidities, limiting their use.
To address these limitations, researchers have investigated symptomatic slow-acting drugs for osteoarthritis (SYSADOAs), such as glucosamine sulfate (GS) and chondroitin sulfate (CS). These treatments are considered safe and well-tolerated but have shown inconsistent results in clinical trials. Collagen derivatives, including collagen hydrolysate (CH) and undenatured collagen (UC), are emerging as potential alternatives, primarily used as nutritional supplements.
Mechanism of Action of Collagen Derivatives
Articular cartilage, a significant component of collagen, plays a crucial role in joint function. Supplementation with collagen hydrolysates is hypothesized to stimulate chondrocytes, the cells responsible for cartilage synthesis, after intestinal absorption and accumulation in cartilage tissue. Preclinical studies have demonstrated that peptides from orally administered collagen hydrolysates accumulate in cartilage tissue within hours, suggesting a potential for cartilage repair.
Recent animal studies have reported promising results, indicating that exogenous administration of collagen derivatives can improve cartilage repair and alleviate OA symptoms. However, limited clinical evidence supports these findings in human studies, necessitating further research.
The Scope of the Review
This scoping review aimed to examine the extent, range, and nature of research on collagen derivatives in OA and cartilage repair. Medline, Scopus, CENTRAL, TOXLINE, and CDSR databases were comprehensively searched, identifying 10,834 records. Forty-one studies met the eligibility criteria, including 16 preclinical studies and 25 clinical studies (four were systematic reviews/meta-analyses). The studies were charted and synthesized using numerical and graphical descriptive statistical methods.
Summary of Findings
Preclinical Studies
Preclinical studies, both in vitro and in vivo, investigated the effects of collagen derivatives on articular cartilage. Four in vitro studies evaluated various collagen hydrolysate (CH) preparations from different sources and molecular weights. These studies measured cartilage metabolism, degradation outcomes, and levels of inflammatory mediators. Three of these studies concluded that CH was either ineffective or detrimental to articular cartilage, highlighting the variability in the effects of different collagen preparations.
In vivo studies, on the other hand, demonstrated the beneficial effects of collagen derivatives on cartilage repair. For instance, studies on squid collagen type II (SCII) and undenatured chicken type II collagen (UC-II) showed improved healing of articular cartilage and reduction in OA-induced damage in animal models. These findings suggest a potential for collagen derivatives to support cartilage repair in OA patients.
Clinical Studies
Clinical studies included randomized placebo-controlled trials, observational studies, and systematic reviews/meta-analyses. The review identified significant positive effects of collagen supplementation on OA symptoms, particularly stiffness, but not consistently on pain and functional limitation. Most clinical trials investigated oral forms of collagen derivatives, with treatment durations ranging from 1.4 to 11 months.
Geographically, most preclinical studies originated from Asia, particularly Japan and China. Clinical studies were more globally distributed, with contributions from Europe, the USA, India, and Turkey. Notably, despite its high number of preclinical studies, Japan did not have any clinical studies.
Gaps in Research
Despite the promising findings, the review identified several gaps in the current research on collagen derivatives for OA and cartilage repair:
-
Limited In Vitro Studies: Only four in vitro studies were identified, highlighting a need for more research to understand the cellular mechanisms of collagen derivatives.
-
Lack of Harmonization: There is a lack of harmonization of endpoints in preclinical studies, making it challenging to compare results across studies.
-
Short-Term Trials: Many clinical trials had relatively short durations, limiting the understanding of the long-term effects of collagen supplementation.
-
Small-Scale Studies: Most studies involved small sample sizes, necessitating larger, randomized, placebo-controlled trials to validate findings.
-
Lack of Radiological Assessment: Few studies investigated radiological changes in OA patients after collagen supplementation, limiting the understanding of its impact on cartilage structure.
-
Limited Scope of OA Types: Most studies focused on knee OA, with limited research on hip or hand OA.
Conclusion and Future Directions
The scoping review suggests that collagen derivatives, particularly CH and UC, are potentially therapeutic options for OA and cartilage repair. Preclinical studies indicate beneficial effects on cartilage repair, while clinical studies have demonstrated improvements in OA symptoms, particularly stiffness. However, the current evidence is not yet robust enough to warrant recommendations from leading scientific societies.
Future research should focus on addressing the identified gaps. Harmonization of endpoints in preclinical studies, long-term randomized placebo-controlled trials with larger populations, and studies involving patients with different types of OA are essential. Additionally, investigating radiological changes and understanding the cellular mechanisms of collagen derivatives will provide a clearer picture of their therapeutic potential.
In conclusion, while collagen derivatives offer a promising alternative to traditional OA treatments, further research is needed to fully understand their efficacy and safety. Patients and healthcare providers should remain informed about ongoing research and emerging evidence to make well-informed decisions regarding OA management.
Recommendations for Patients and Healthcare Providers
Given the current evidence, patients with OA considering collagen supplementation should consult with their healthcare providers to understand the potential benefits and limitations. To provide evidence-based recommendations, healthcare providers should stay updated with ongoing research and emerging findings.
Key Considerations for Patients:
-
Consult Healthcare Providers: Before starting any new supplement, including collagen derivatives, it is essential to discuss it with a healthcare provider to ensure it aligns with individual health needs and conditions.
-
Monitor Symptoms: Patients should closely monitor their symptoms and report any changes or side effects to their healthcare provider.
-
Adherence to Treatment: Consistent adherence to the prescribed treatment regimen is crucial for evaluating the effectiveness of collagen supplementation.
Key Considerations for Healthcare Providers:
-
Stay Updated: Healthcare providers should keep abreast of the latest research and guidelines on collagen derivatives and OA management.
-
Individualized Treatment: Treatment plans should be personalized, considering the patient's overall health, comorbidities, and treatment preferences.
-
Educate Patients: Providers should educate patients about collagen supplementation's potential benefits and limitations, ensuring they have realistic expectations.
Conclusion
Collagen derivatives represent a promising avenue for managing osteoarthritis and cartilage repair. Preclinical and clinical studies have demonstrated potential benefits, particularly in improving symptoms of OA. However, the current evidence base is insufficient to form definitive conclusions. Future research should address the gaps to provide more robust and comprehensive evidence. In the meantime, patients and healthcare providers should engage in informed discussions to explore the potential role of collagen derivatives in OA management.
For further information, you can access the complete study and additional resources at
National Center for Biotechnology Information. This study provides a detailed analysis of the effects of collagen derivatives in OA and cartilage repair, contributing valuable insights to the ongoing research in this field.
